Peregrine Capital Management LLC Invests $2.29 Million in Haemonetics Corporation $HAE

Key Points

• Peregrine Capital Management LLC opened a new position in Haemonetics (NYSE:HAE), buying 28,610 shares valued at about $2.29 million and representing roughly 0.06% of the company; institutional investors own approximately 99.67% of HAE.
• Wall Street sentiment is cautiously positive with a MarketBeat consensus rating of "Moderate Buy" and a consensus target price of $82.78 (ratings breakdown: 1 Strong Buy, 6 Buy, 4 Hold), though several brokers have recently adjusted targets in the roughly $70–$88 range.
• Haemonetics beat recent quarterly estimates (EPS $1.31 vs. $1.27; revenue $339M vs. $331.9M) and issued FY2026 guidance of $4.90–$5.00 EPS, roughly in line with analysts' average forecast of $4.95.

Peregrine Capital Management LLC acquired a new position in Haemonetics Corporation (NYSE:HAE - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 28,610 shares of the medical instruments supplier's stock, valued at approximately $2,293,000. Peregrine Capital Management LLC owned approximately 0.06% of Haemonetics as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. True Wealth Design LLC lifted its position in shares of Haemonetics by 6,700.0% in the fourth quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier's stock worth $27,000 after purchasing an additional 335 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier's stock worth $31,000 after purchasing an additional 396 shares in the last quarter. Versant Capital Management Inc lifted its position in shares of Haemonetics by 216.4% in the third quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier's stock worth $40,000 after purchasing an additional 567 shares in the last quarter. Bayforest Capital Ltd bought a new stake in shares of Haemonetics in the fourth quarter worth $40,000. Finally, Caitong International Asset Management Co. Ltd lifted its position in shares of Haemonetics by 20,925.0% in the third quarter. Caitong International Asset Management Co. Ltd now owns 841 shares of the medical instruments supplier's stock worth $41,000 after purchasing an additional 837 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on HAE. Citigroup cut their price objective on shares of Haemonetics from $75.00 to $70.00 and set a "neutral" rating on the stock in a research report on Wednesday, March 11th. Robert W. Baird set a $81.00 price objective on shares of Haemonetics in a research report on Friday, February 6th. Weiss Ratings reissued a "hold (c)" rating on shares of Haemonetics in a research report on Monday, December 29th. BTIG Research reissued a "buy" rating and issued a $88.00 price objective on shares of Haemonetics in a research report on Friday, February 6th. Finally, Mizuho cut their price objective on shares of Haemonetics from $80.00 to $70.00 and set an "outperform" rating on the stock in a research report on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, Haemonetics has an average rating of "Moderate Buy" and a consensus target price of $82.78.

Haemonetics Price Performance

Shares of HAE opened at $60.01 on Friday. The company has a market cap of $2.79 billion, a price-to-earnings ratio of 16.53, a PEG ratio of 1.17 and a beta of 0.36. Haemonetics Corporation has a 1-year low of $47.31 and a 1-year high of $87.32. The company's fifty day simple moving average is $59.93 and its 200 day simple moving average is $66.07. The company has a current ratio of 1.75, a quick ratio of 1.15 and a debt-to-equity ratio of 1.01.

Haemonetics (NYSE:HAE - Get Free Report) last issued its earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share for the quarter, topping analysts' consensus estimates of $1.27 by $0.04. The business had revenue of $338.97 million for the quarter, compared to the consensus estimate of $331.90 million. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The firm's revenue for the quarter was down 2.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.19 earnings per share. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. On average, research analysts forecast that Haemonetics Corporation will post 4.95 earnings per share for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company's offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company's product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.